| Stephanie Katz, OTR/L, CHT | |
|
1020 19th St Nw Lowr Ll20, Washington, DC 20036-6109 | |
| (914) 924-5739 | |
| Not Available |
| Full Name | Stephanie Katz |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Hand |
| Location | 1020 19th St Nw Lowr Ll20, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134983018 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XH1200X | Occupational Therapist - Hand | (District Of Columbia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Katz, OTR/L, CHT 909 Webster St Nw Unit 3, Washington, DC 20011-7129 Ph: () - | Stephanie Katz, OTR/L, CHT 1020 19th St Nw Lowr Ll20, Washington, DC 20036-6109 Ph: (914) 924-5739 |
News Archive
A multi-institutional international study led by scientists at The University of Texas MD Anderson Cancer Center has revealed new information about how molecules called long non-coding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-1 has been shown to regulate breast cancer progression.
Two types of touch information — the feel of an object and the position of an animal's limb — have long been thought to flow into the brain via different channels and be integrated in sophisticated processing regions.
Researchers have long been aware that the progressive loss of muscle mass and bone density is a natural part of aging. But little work has investigated how muscle tissue affects the inner and outer layers of bone microstructure.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.
NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.
› Verified 6 days ago
Miss Samora Casimir, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 443-802-7824 | |
Petra Doyle, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 201 8th St Ne, Suite 301, Washington, DC 20002 Phone: 202-544-5439 | |
Lisa George, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4400 Jenifer St Nw, Suite 280, Washington, DC 20015 Phone: 202-244-8089 | |
Andrea L. Meehan, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 50 Irving St Nw, Washington, DC 20422 Phone: 202-745-8000 | |
Samantha Fulp, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 101 T St Ne, Washington, DC 20002 Phone: 956-278-0770 | |
Tsegie Kassahun, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1818 Newton St Nw, Washington, DC 20010 Phone: 202-328-7400 | |
Dr. Nikia Brocks, OTD,OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2411 32nd St Se, Washington, DC 20020 Phone: 202-575-5404 Fax: 301-576-5404 |